Key Drivers
- High margins
- Working‑capital drain
- Poor FCF conversion
AIAI Summary
ADMA has effectively become a commercially driven, cash‑flowing specialty plasma company where ASCENIV and yield‑enhanced manufacturing are the primary drivers of its premium valuation—so the investment thesis now hinges on execution (plasma supply, FDA lot releases, payer coverage) and rapid working‑capital improvement to convert strong reported margins into durable free cash flow.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Working‑capital drain
- •Poor FCF conversion
ADMA delivers high profitability and low leverage but faces heavy working‑capital drag and weak free‑cash‑flow conversion while trading at rich multiples.
Price Behavior
Key Price Behavior Insights:
- •Short‑term downtrend
- •Lower highs
- •Clustered support
ADMA is in a short‑term downtrend after trading below its last month SMA (~$15.65) and falling ~11% over the past month, with nearby support around $15.10–$15.80 and resistance at $16.30–$16.60.
~11% decline from 2026-02-20 to 2026-03-20 indicating negative momentum
Sentiment & News
Key News Insights:
- •Revenue acceleration
- •Large buyback
- •SG‑001 pre‑IND
ADMA Biologics reported robust FY2025 and Q4 results with strong Asceniv growth, a $125M accelerated buyback, upgraded analyst sentiment, and pipeline progress toward a 2026 SG‑001 pre‑IND while management targets >$635M revenue for 2026.
Positive commercial momentum and capital returns should support near‑term share appreciation and margin expansion, though clinical and execution risks remain
Similar Companies in Healthcare
Other companies in the same sector with AI ratings